erythromycin propionate-n-acetylcysteinate has been researched along with vasoactive intestinal peptide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badran, B; El Zein, N; Sariban, E | 1 |
1 other study(ies) available for erythromycin propionate-n-acetylcysteinate and vasoactive intestinal peptide
| Article | Year |
|---|---|
VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1.
Topics: Acetylcysteine; Animals; Calcium; CD18 Antigens; Cell Line; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Erythromycin; Humans; Matrix Metalloproteinase 9; Monocytes; Neutrophils; Polymerase Chain Reaction; Receptors, Complement 3b; Receptors, Formyl Peptide; Receptors, Lipoxin; Receptors, Vasoactive Intestinal Polypeptide, Type I; Signal Transduction; Transfection; Vasoactive Intestinal Peptide | 2008 |